ADIL logo

ADIAL PHARMACEUTICALS INC

ADILNASDAQ
🏆 #4979 by market capEarnings Nov 11US Equity
$4.15▲ $0.11 (+2.72%)
🌙 After hours$4.15▲ 0.00%Regular close · extended-hours price shown
🔔
Track ADIL
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 2.7%
7d▼ 5.4%
14d▼ 19.9%
30d▼ 26.9%
ytd▼ 26.2%
1y▼ 50.3%
🏦Market Cap
$11M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
80
Good

Trading Snapshot

Day Range
$4.13 – $4.21
52-Week Range
$1.31 – $249.81
Volume
$1.64B
Avg Volume
$1.88B
Shares Outstanding
2.6M
Next Earnings
Dec 14, 2026

Fundamentals Snapshot

Annual Revenue
$4M
Last Q Revenue
$1M
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-16.57
Dividend Yield
—
Dilution (1yr)
+49.4%

Why Investors Own ADIL

  • ✓High-growth profile — revenue up +36.2% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 63% gross margin and 29% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ADIL logo

ADIAL PHARMACEUTICALS INC

ADIL
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$8M▼ −5.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$6M▼ −6.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.1M▲ +49.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$6M▲ +$2M YoY
StockOtter · stockotter.space

About ADIAL PHARMACEUTICALS INC

Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
80/100

Analyst Ratings

ⓘ
Consensus
Buy
10 analysts
Strong Buy2
Buy6
Hold2
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

GlobeNewsWire·Aug 25

Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

GLEN ALLEN, Va., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company's Compensation Committee has granted a new employee stock option t

GlobeNewsWire·Aug 17

Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update

Completed acquisition of Azora Therapeutics, adding AT177, a fully synthetic, oral, colon-targeted aryl hydrocarbon receptor (“Ahr”) agonist in development for ulcerative colitis, to its pipeline